Dx Deals: Quest Closes PathAI Partial Acquisition and Strategic Alliance
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.
The way the No Surprises Act is implemented would essentially allow private health plans to set out-of-network rates in billing disputes.
Meant to be temporary, remote regulatory assessments proved so successful that the agency will not only continue, but expand their use.
Independent labs accrued a profit of at least $10 on each PCR COVID-19 test performed in the period from May to December 2020, study says.
Some of the lab industry’s biggest players are teaming up to develop new monkeypox diagnostics in response to the current outbreak.
A hostile government policy has done little to slow consolidation of independent medical practices and hospitals.
Now that the finishing touches have been put on LDT-related legislation, what is the likelihood that it will pass?
Two of the biggest merger and acquisition-related deals that came down in May involved BioMérieux and Sema4
Senate committee members propose a modified version of legislation allowing the FDA to continue to regulate LDTs on a risk-tiered basis.
Companies will explore LabDroid’s capacity to automate sample preparation workflows for long-read sequencing systems.
Companies are using the lessons learned from COVID-19 to get out of the box quickly in developing test kits for monkeypox.